New drug shows promise against superbug fungus in small trial
NCT ID NCT04148287
First seen Jun 26, 2026 · Last updated Jun 26, 2026 · Updated 1 time
Summary
This Phase 2 trial tested an experimental antifungal drug called APX001 (fosmanogepix) in 9 adults with blood or deep-organ infections caused by Candida auris, a fungus that often resists standard treatments. The drug was given by IV or mouth for up to 42 days. The goal was to see if the infection cleared and patients survived without needing other antifungals. Because the study was very small and had no placebo group, the results are encouraging but not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
APX001 (fosmanogepix), an antifungal drug given by IV or mouth
What this could lead to
If it works, this could offer a new treatment option for people with dangerous Candida auris infections that resist standard antifungals.
What could go wrong
This was a very small study (9 people) with no comparison group, so results are preliminary. The drug may not work as well in larger, more diverse groups, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CANDIDEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Milpark Academic Trauma Centre
Johannesburg, Gauteng, 2193, South Africa
-
Netcare Union Hospital Trauma Surgeons
Alberton, Gauteng, 1449, South Africa